Clinuvel Pharmaceuticals (ASX:CUV) appointed specialty pharmaceutical firm Diligens Salud, part of the Scienza Group, to market and sell the Scenesse (afamelanotide) therapy in Argentina, according to a Friday filing with the Australian bourse.
The therapy, used to treat patients with erythropoietic protoporphyria, will be facilitated under maned-patient programs, with both parties collaborating on long-term formal marketing authorization, the filing said.
Erythropoietic protoporphyria is a genetic condition characterized by skin sensitivity to sunlight and artificial light.
The company's shares were up almost 1% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。